Immunotherapy, especially targeting checkpoint inhibitors, such as programmed cell death protein-1/programmed cell death protein-ligand 1 (PD1/PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4), is often used in people with NSCLC. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.